SEC Company Response from REGENXBIO Inc. (RGNX) (CIK 0001590877) (RGNX) — Sep 14, 2015
REGENXBIO Inc. (RGNX) (CIK 0001590877)
Date: Sept. 14, 2015 · CIK: 0001590877 · Accession: 0001193125-15-319502
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-206430
Letter
VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Attention: Jeffrey P. Riedler John Krug Re: REGENXBIO Inc. Registration Statement on Form S-1 (File No. 333-206430) Request for Acceleration of Effective Date
Dear Mr. Riedler:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, REGENXBIO Inc. (the “Registrant”) hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-206430) (as amended, the “Registration Statement”), so that it may become effective at 5:00 p.m. Eastern Time on September 16, 2015, or as soon thereafter as practicable. By separate letter, the representatives of the underwriters of the issuance of the securities being registered join this request for acceleration.
The Registrant hereby acknowledges that:
(i) should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
(ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
(iii) the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
[Signature Page Follows]
Please do not hesitate to contact our legal counsel, Albert Vanderlaan at (617) 648-9298 if you have any questions or would like additional information regarding this matter.
Sincerely,
REGENXBIO Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP REGENXBIO INC. 9712 MEDICAL CENTER DRIVE, SUITE 100 ROCKVILLE, MD 20850 September 14, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler Preston Brewer John Krug Re: REGENXBIO Inc. Registration Statement on Form S-1 (File No. 333-206430) Request for Acceleration of Effective Date Dear Mr. Riedler: Pursuant to Rule 461 under the Securities Act of 1933, as amended, REGENXBIO Inc. (the “Registrant”) hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-206430) (as amended, the “Registration Statement”), so that it may become effective at 5:00 p.m. Eastern Time on September 16, 2015, or as soon thereafter as practicable. By separate letter, the representatives of the underwriters of the issuance of the securities being registered join this request for acceleration. The Registrant hereby acknowledges that: (i) should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; (ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and (iii) the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. [Signature Page Follows] 1 Please do not hesitate to contact our legal counsel, Albert Vanderlaan at (617) 648-9298 if you have any questions or would like additional information regarding this matter. Sincerely, REGENXBIO Inc. By: /s/ Kenneth T. Mills Kenneth T. Mills President and Chief Executive Officer cc: Jay K. Hachigian Richard R. Hesp, Esq. Keith J. Scherer, Esq. Albert W. Vanderlaan, Esq. Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP 2